In the landmark IMbrave150 trial, patients with advanced HCC had improved survival with atezolizumab (PD-L1 inhibitor) and bevacizumab (vascular endothelial growth factor receptor (VEGFR) inhibitor) compared with sorafenib (10). This evidence concerns the gene KDR and hepatocellular carcinoma.